Clinical Partners has raised new debt facilities
Clinical Partners Ltd. has successfully restructured and upsized its debt facilities to better reflect the scale of the business. The company increased its original US$9.4 million facility, comprising a US$3.4 million term loan and a US$6 million revolving credit facility (RCF), to a US$27 million RCF.
The new facility was secured on improved pricing and with enhanced documentation flexibility, providing additional headroom to support the company’s long-term strategy, including organic and acquisitive growth, as well as indirectly supporting a dividend to shareholders.
Clinical Partners is a leading provider of mental health services, working both privately and with the National Health Service (NHS) to help people of all ages achieve improved mental health outcomes. Through in-person and remote appointments, the company connects thousands of patients with senior clinicians across a broad range of mental health conditions, including autism, attention deficit hyperactivity disorder (ADHD), anxiety and depression.
Oaklins Cavendish, one of Oaklins’ member firms in the UK, advised Clinical Partners in raising new debt facilities. The team supported the company throughout the process, helping to secure a structure aligned with its growth ambitions and long-term strategic objectives.
Talk to the deal team
David Fitzgerald
Oaklins Cavendish
Related deals
Rare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreGSP Group has secured an upsized growth refinancing package from HSBC
The GSP Group has refinanced its growth facilities through an upsized financing package provided by HSBC.
Learn moreLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn more